159989-64-7
159989-64-7 结构式
基本信息
尼非那韦
娜芙维亚
萘非那韦
奈非那韦杂质
甲磺酸萘非那韦
2-[(2R,3R)-2-羟基-3-[(3-羟基-2-甲基苯甲酰)氨基]-4-(苯基硫)丁基]-(3S,4aS,8aS)-N-叔丁基十氢异喹啉-3-甲酰胺
nefinavir
NELFINAVIR
NELFINAVIR-12
8a-beta))-a-bet
NELFINAVIR USP/EP/BP
Nelfinavir Regeoisomer
AG 1341
AG-1341
AG1341
Nelfinavir & Nelfinavir Mesylate
3-isoquinolinecarboxamide,n-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hy
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-15287 | 甲磺酸萘非那韦 Nelfinavir | 159989-64-7 | 2mg | 600元 |
| 2024/04/30 | HY-15287 | 甲磺酸萘非那韦 Nelfinavir | 159989-64-7 | 10mg | 1650元 |
| 2024/04/30 | HY-15287 | 甲磺酸萘非那韦 Nelfinavir | 159989-64-7 | 50mg | 3800元 |
常见问题列表
|
HIV-1
|
Nelfinavir (AG1341) (1-10 μM; 48 hours) inhibits the proliferation of multiple myeloma cells.
Nelfinavir inhibits 26S chymotrypsin-like proteasome activity, impairs proliferation and triggers apoptosis of the myeloma cell lines and fresh plasma cells.
Nelfinavir (1-10 μM; 17 hours) induces apoptosis of multiple myeloma cell lines.
Nelfinavir (5 μM; 0-24 hours) decreases the phosphorylation of AKT.
Nelfinavir activates the cleavage of caspase-3, decreases the phosphorylation of AKT, STAT-3, ERK1/2, and activates the pro-apoptotic pathway of the unfolded protein response system.
Cell Proliferation Assay
| Cell Line: | RPMI, LP1, U266, OPM2 and MM1S cells |
| Concentration: | 1, 2, 5, 10 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines in a dose-dependent manner with an IC 50 of 1-5 μM. |
Apoptosis Analysis
| Cell Line: | LP1 and U266 cells |
| Concentration: | 1-10 μM |
| Incubation Time: | 17 hours |
| Result: | Induced a dose-dependent increase in the percentage of annexin V + /propidium iodide + cells. |
Western Blot Analysis
| Cell Line: | U266 cells |
| Concentration: | 5 μM |
| Incubation Time: | 0-24 hours |
| Result: | The level of AKT phosphorylation in U266 cells decreased. |
Nelfinavir (AG1341) (75 mg/kg; i.p.; 5 days a week for 21 days) decreases multiple myeloma cell growth in NOD/SCID mice.
| Animal Model: | NOD/SCID mice (bearing U266-luc cells) |
| Dosage: | 75 mg/kg |
| Administration: | I.p.; 5 days a week for 21 days |
| Result: | Decreased MM cell growth in NOD/SCID mice. |